Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care (LUS-COVID19)

COVID Clinical Trial

— LUS-COVID19  

Official title:

Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04393402
• Other study ID #: 20reamedcovid03
• Status: Recruiting
• Start date: March 20, 2020
• Est. completion date: December 31, 2020

Study information

• Verified date: May 2020
• Source: Centre Hospitalier Universitaire de Nice
• Contact: Jean DELLAMONICA, MD, PhD
• Phone: +334 92 03 55 10
• Email: dellamonica.j[@]chu-nice.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

It might be necessary with Sars-Cov2 pneumopathy patient to repeat thoracic images, the tomodensitometry ones in particular. This task is difficult and nearly impossible for several reasons: respiratory and hemodynamic unstable patient, prone position and due to the high contagious nature of the disease.

The lung ultrasound is an easy tool, fast (between 5 and 10 minutes) and as a limited training.

In the context of the Sars-Cov2 epidemic, Buonsenso and al case report depict the first lung ultrasound for a Covid 19 patient.

Peng and al in Intensive Care Medicine accentuate the usefulness of this particular technic.

In the American Journal of Respiratory and Critical Care Medicine, a study has been published as a point-of-care, in which the doctors reported using the lung ultrasound with intensive and critical care patient.

In Critical Care 2016, it has been showed that ultrasound allowed with neat precisions, to predict severe ARDS patient response to the prone position, all-cause.

Another researchers team found a good correlation between lung ultrasound, the SOFA, APACHE II, CPIS score, and patient mortality.

And a new applicability in the pulmonary recruitment by PEEP titration has been presented.

The aim of this study is to evaluate the lung ultrasound in Covid19 ARDS.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 14
• Est. completion date: December 31, 2020
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 95 Years

Eligibility

Inclusion Criteria:

• Diagnosed Sars-Cov2 patient, with PCR method qualitative or quantitative as usual.

• Intensive or critical care admission

• ARDS with PaO2/FiO2 <300 at the admission

• Ventilatory support or oxygen-therapy

Exclusion Criteria:

• Age < 18 years-old

• Pregnancy

• Patient with tutor- or curatorship or in prison

Related Conditions & MeSH terms

• Communicable Diseases
• COVID
• Infection

Intervention

Procedure:
• lung ultrasound (LUS)
Patients with Covid-19 Disease and admitted in critical care unit will be performed a LUS

Locations

Country	Name	City	State
France	CHU de Nice	Nice

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	LUS applicability with COVID 19	In dorsal position, or in prone position, the two hemithorax will be subdivided in 6 parts, and a score will be attributed with the following criteria : A-Lines (0 point), > 3 B-lines (1 point), B-Lines coalscent (2 points), and pulmonary consolidation (3 points). For the echography we can use a convexe sonde, or a "cardiac" sonde.	10 months
Secondary	Radiographic correlation (chest Xray and tomodensitometry)	Comparison between Xray / CT scan exam and LUS	10 months
Secondary	LUS Mortality prediction	according to LUS score, ventilatory mode and parameters, medical history and bood analysis results	10 months
Secondary	Prediction of Prone position response	comparison of LUS score depending of the position used for performing LUS	10 months